Helping to keep families healthy and free from malaria since the mid-1980s.
- From 2016 to 2018, more than 14,000 cases of malaria were confirmed by testing and then treated using artemisinin-based combination therapy, as recommended by the World Health Organization.
- In this same time period, more than 18,000 pregnant women received intermittent preventive treatment for malaria under direct observation—thereby providing protection from the dangers of malaria in pregnancy.
- The percentage of cases of malaria at Jhpiego-supported sites that were treated according to Cameroon’s national guidelines increased from 70% in 2012 to 89% in 2018.
- Jhpiego strengthened the Ministry of Health’s ability to respond to epidemics by supporting development of national infection prevention and control (IPC) guidelines, training a pool of national IPC trainers and three Ebola Rapid Response Teams, and strengthening the capacity of over 90 providers from 77 health facilities in Kribi, Lolodorf and Ebolowa districts via IPC training and donation of essential IPC equipment.
Our Work in Cameroon
Malaria is the leading cause of morbidity and mortality in Chad and Cameroon, and is particularly dangerous for children and pregnant women. With support from ExxonMobil, Jhpiego is strengthening the capacity of the Chadian and Cameroonian Ministries of Health, the National Malaria Control Programs, health providers and community health volunteers to provide high-quality malaria prevention and treatment for nearly 1,180,000 people living in ten malaria-endemic districts along ExxonMobil’s 1,070-kilometer pipeline. The nine districts are Doba, Bodo, Béboto, Bébédjia, Goré, Bessao, Laramanaye, Donia, Kara (in Chad), and Kribi (in Cameroon). In addition to leading the development of national-level malaria guidelines, training manuals and reference materials, Jhpiego has trained health providers, supervisors and community health volunteers to provide health services and/or health messages. These interventions have resulted in provision of lifesaving treatment to people with confirmed cased of malaria and improved coverage for intermittent preventive treatment of malaria among pregnant women.
Impact Malaria is a global project of the U.S. President’s Malaria Initiative to reduce mortality and morbidity caused by malaria. Implemented by a consortium of organizations led by PSI, the project is funded by the U.S. Agency for International Development. In close collaboration with the National Malaria Control Program, other sections of the Ministry of Health and various implementing partners, Impact Malaria is designed to improve malaria service delivery via the following objectives: 1) improve the quality of and access to malaria case management and prevention of malaria in pregnancy; 2) improve the quality of and access to other malaria drug-based approaches and provide support to pilot/scale up newer malaria drug-based approaches; and 3) provide global technical leadership, support operational research and advance program learning.